EPAM Systems (EPAM): Exploring Valuation After Analyst Upgrade and Strong AI-Driven Results

EPAM Systems (NYSE:EPAM) is back in the spotlight after reporting quarterly results that beat forecasts, powered by strong demand for AI-focused services and digital modernization. The company also gave its outlook a lift, projecting annual revenue growth of 13% to 15%. Adding to the momentum, EPAM received an analyst upgrade to ‘Buy’, highlighting how three straight quarters of faster organic revenue and its completed post-Ukraine restructuring have changed the conversation for both investors and clients.

The news has injected some new energy into a stock that has seen mixed performance over the past year. EPAM’s return for the year sits at about -10%, and longer-term holders are still in the red over three and five years. However, the past month has delivered a 17% gain, suggesting that the market is starting to see potential as the company accelerates in its core and emerging business lines. There is an undercurrent of shifting risk perceptions here, with improvements in sales execution and expanding margins getting recognition even as sector challenges remain.

With the share price rallying on upgraded expectations, the key question for investors is whether EPAM Systems still trades at an attractive valuation or if the market is already pricing in the next phase of growth.

Most Popular Narrative: 17% Undervalued

According to the most widely followed narrative, EPAM Systems is currently considered undervalued. Analysts expect a multi-year earnings expansion, with the company's share price trading well below consensus fair value based on future growth projections.

"EPAM's strategic investments in AI-native services, proprietary platforms (such as DIAL and AI/RUN), and upskilling of over 80% of its workforce have positioned it as a transformation partner for clients moving beyond pilot AI programs to large-scale deployments. This supports sustainable revenue growth and the potential for improved net margins as EPAM moves up the value chain."

Want to know what’s fueling the narrative that EPAM is poised for a rebound? Most valuation models hinge on bold projections about future revenues and profits, as well as a shifting mix of business lines. Curious which assumptions justify a double-digit discount to fair value? Find out which surprising financial forecasts are powering this bullish consensus.

Result: Fair Value of $212.69 (UNDERVALUED)

However, rising automation and persistent wage inflation could threaten EPAM’s margins. These factors could potentially challenge the bullish outlook if these headwinds intensify.

Another View: Our DCF Model

Taking a different approach, our SWS DCF model also suggests EPAM might be undervalued by looking at future cash flows instead of focusing solely on earnings multiples. Does this second check strengthen the bullish case, or does it raise new questions?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out EPAM Systems for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own EPAM Systems Narrative

If you’d rather rely on your own analysis or simply want a second opinion, it’s easy to craft a personal perspective in under three minutes. Do it your way.

A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding EPAM Systems.

Looking for more investment ideas?

Why stop at one winner? Take your strategy up a notch and put your watchlist to work with three standout opportunities you won’t want to overlook.

• Unlock high-yield potential by checking out top companies delivering reliable income with attractive returns using our handpicked dividend stocks with yields > 3%.
• Tap into emerging breakthroughs by seeking out trends in medical innovation and patient care advancements with our leading healthcare AI stocks.
• Get ahead of the curve with future-focused companies at bargain prices, each featured in the smart undervalued stocks based on cash flows.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com